Request Information
Request Information
Dr. Gustavo Cumbo-Nacheli
A 47-year-old female patient with a previous diagnosis of a right knee malignant peripheral nerve sheath tumor, confirmed neurofibromatosis presented with a 1cm nodule on her right lung; suspicious for metastatic malignancy. The lesion was not expected to be palpable and a dye marking procedure using the MONARCH® Platform was requested prior to robotic resection.
One pathway was created and used to navigate near this nodule, which was small (10mm) and in a difficult area to access in the lung with no visible bronchus sign coming within several centimeters of the target (Fig.1). Once the MONARCH® bronchoscope was navigated to a satisfactory location in close proximity to the target (Fig.2), fluoro was used to verify location, and a 19g Olympus PeriView FLEX needle was used to deliver the dyes into or near the lesion. The needle was inserted through the MONARCH® bronchoscope using fluoroscopic guidance, and then extended from its sheath. Using a 1.0cc slip-tip syringe, 0.75cc methylene blue was injected without an air chaser. The needle was not primed with dye prior to inserting it into the scope to prevent leakage. Next, leaving the scope and needle in place, and using a separate 1.0 cc slip-tip syringe, 0.75cc indocyanine green was injected under fluoroscopic guidance and without an air chaser. This technique was developed at the cardiothoracic surgeon’s request, who finds that this combination of dyes at these doses provides adequate visualization of the area of interest without over-dyeing the area. Effective dye was placed within 1cm of the nodule & robotic resection was performed (Figs.3-5).
"Final Diagnosis - Metastatic Malignant Peripheral Nerve Sheath Tumor"
The Fused Navigation Technology equipped in the MONARCH® Platform allowed me to precisely dye a nodule area of concern several centimeters away from the nearest airway. Tissue analysis reported metastatic malignant peripheral nerve sheath tumor surrounded by adequate margin in the resected specimen
Dr. Cumbo-Nacheli is an Interventional Pulmonologist at Spectrum Health, Michigan
Indications for Use: The MONARCH® Platform and its accessories are intended to provide bronchoscopic visualization of and access to patient airways for diagnostic and therapeutic procedures.
Important Safety Statement: Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. It is uncommon for patients to experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
This document reflects the techniques, approaches and opinions of the individual physician. This Auris sponsored document is not intended to be used as a training guide. Other physicians may employ different techniques. The steps demonstrated may not be the complete steps of the procedure. Individual physician preference and experience, as well as patient needs, may dictate variation in procedure steps. Before using any medical device, review all relevant package inserts with particular attention to the indications, contraindications, warnings and precautions, and steps for use of the device(s).
Dr Gustavo Cumbo-Nacheli is compensated by and writing on behalf of Auris Health and must present information in accordance with applicable FDA requirements.
Bronchoscopy:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.